Raymond James & Associates Alector, Inc. Transaction History

Raymond James & Associates

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$7.65 - $14.24 $269,731 - $502,088	35,259 Added 45.44%	112,859 $1.15 Million
Q1 2022 May 11, 2022	BUY	$13.02 - $20.78 $1.01 Million - $1.61 Million	77,600 New	77,600 $1.11 Million
Q2 2021 Aug 11, 2021	SELL	$15.5 - $22.48 $521,885 - $756,901	-33,670 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$14.84 - $22.23 $512,499 - $767,713	-34,535 Reduced 50.63%	33,670 $678,000
Q4 2020 Feb 12, 2021	BUY	$9.4 - $16.7 $363,112 - $645,104	38,629 Added 130.61%	68,205 $1.03 Million
Q3 2020 Nov 04, 2020	BUY	$10.54 - $24.96 $311,731 - $738,216	29,576 New	29,576 $312,000
Q2 2020 Jul 28, 2020	SELL	$21.87 - $33.11 $192,718 - $291,765	-8,812 Closed	0 $0
Q1 2020 Apr 21, 2020	BUY	$16.25 - $35.28 $143,195 - $310,887	8,812 New	8,812 $213,000

168

57.8M

146K

90.8K

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $159M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.